The popular cannabis resource applauds Mary’s Medicinals achievements in developing standardized dosage with transdermal cannabinoid therapies.

United Patients Group (http://www.unitedpatientsgroup.com), the leading medical cannabis information and educational site, is proud to award Mary’s Medicinals’ transdermal and topical cannabinoid therapies, designed to provide sustained relief to patients who suffer from chronic pain, its Seal of Approval. United Patients Group’s founder John Malanca says Mary’s standardized dosages, which take the guesswork out of administration, and positive patient feedback set Mary’s products apart.

Mary’s Medicinals transdermal products have only been available in Colorado and Washington state, but they are now available in over 100 dispensaries in both Northern and Southern California. Mary’s Medicinals’ founder and president Nicole Smith says her company developed the line to fill the need for standardized dosing using an effective sustained-delivery format used by many pharmaceutical companies today.

“An increasing number of people are looking to cannabis, not to escape reality or get high, but for relief from debilitating medical conditions like chronic pain,” said Malanca. “United Patients Group reserves its Seal of Approval for products that help medical patients, and this award recognizes Mary’s products for doing just that.”

Mary’s Medicinals are available in a variety of formats, including:

Mary’s Transdermal Patches –
For sustained, targeted relief without the inconvenience of re-medicating, Mary’s Medicinals award-winning patches, offers two-inch square transdermal patches that can be applied to any part of the body. Mary’s patches are currently available in single-dose packaging. Mary’s six different formulations include: CBD, CBD-THC, THCA, and CBN available in 10 mg dosages, and THC-Sativa and THC-Indica in 20mg dosages.

Mary’s Transdermal Gel Pen –
An accompaniment to its patches, Mary’s transdermal gel pens enable patients suffering from chronic pain to treat sharp spikes of breakthrough pain. Mary’s THC-Indica, THC-Sativa, CBD, and CBN formulas can be blended to achieve a wide range of cannabinoid ratios.

The child-resistant pen dispenses 50 doses containing 2 mg of active cannabinoids, which is applied and gently rubbed into the skin. Although the bioavailability of the cannabinoids in Mary’s transdermal gel is similar to the patch, it is more intense—meaning its effects will be felt faster, but for a shorter duration.

Mary’s Transdermal / Topical Compound –
Mary’s has harnessed the internal and external healing powers of Cannabichromene (CBC) in a compound activated by Mary’s proprietary carrier agent blend. CBC is a cannabinoid that has antibacterial, antimicrobial, and antifungal properties that relieves pain and reduces swelling, while increasing blood circulation.

To learn more about Mary’s products or where to purchase, visit: http://www.MarysMedicinals.com

The post Mary’s Medicinals Transdermal Cannabinoid Products Receive United Patients Group Seal of Approval appeared first on United Patients Group.